RRPV BoNT-NMJ
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
|---|---|
| State: | District of Columbia |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Posted Date: | Apr 20, 2026 |
| Due Date: | May 11, 2026 |
| Solicitation No: | SSN-BARDA-04202026 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Sources Sought (Original)
- Original Published Date: Apr 20, 2026 09:39 am EDT
- Original Response Date: May 11, 2026 01:00 pm EDT
- Inactive Policy: 15 days after response date
- Original Inactive Date: May 26, 2026
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: 6505 - DRUGS AND BIOLOGICALS
-
NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
-
Place of Performance:
Washington , DCUSA
Botulinum neurotoxins (BoNT/A–G) inhibit acetylcholine release at the neuromuscular junction through cleavage of SNARE proteins (e.g., SNAP-25, VAMP, syntaxin). Currently, BoNT characterization, including toxin potency and neutralization by medical countermeasures, is measured using mouse-based bioassays, primarily the Mouse Potency Assay (MPA) and Mouse Neutralization Assay (MNA), respectively.
There is increasing scientific, ethical, and regulatory interest in transitioning to human-relevant in vitro systems that can provide mechanistic insight while reducing reliance on animal testing. NMJ micro-physiological systems may provide a biologically relevant platform capable of measuring BoNT potency and evaluating countermeasure efficacy.
BARDA is interested in understanding whether NMJ-based in vitro platforms could support future development of validated assays capable of reducing and potentially replacing reliance on mouse bioassays for BoNT potency and neutralization measurements, with specific interest in systems that can show recovery of neuronal signaling and thereby be appropriate for medical countermeasures evaluation.
- O’NEILL HOUSE OFFICE BUILDING
- WASHINGTON , DC 20515
- USA
- Kathy Garee
- rrpv-contracts@ati.org
- Yifan Yang
- yifan.yang@hhs.gov
- Apr 20, 2026 09:39 am EDTSources Sought (Original)
See Also
Basic Information Solicitation Number Doc849163 Title RFP - Interoperability and Patient Access System
District of Columbia
Due by 10/16/2026
Follow Special Notice for the Federal Transit Administration's Transit Innovation Showcase: Request for
TRANSPORTATION, DEPARTMENT OF
Due by 10/16/2026